Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Capillar Equity Investment I on its sale of shares in Nordic Surface Group
Mandate

Vinge advises Capillar Equity Investment I on its sale of shares in Nordic Surface Group

January 15, 2021 M&A

Vinge is advising Capillar Equity Investment I in connection with the sale of shares in Nordic Surface Group (“NSG”) to a funds managed by Litorina and Bragnum, respectivley. NSG’s management will remain as significant co-owners in the group consisting of six local market leaders formed by Capillar Equity in 2020.

The company offers painting and other surface services such as flooring, tiling and facade finishing in Sweden and combined reported a revenue of SEK 1bn with 800 FTEs in 2020.

Closing of the transaction is subject to applicable competition law approvals and other customary closing conditions.

The Vinge team advising on the transaction includes partner Christina Kokko with the associates Michaela Cronemyr, Johanna Wiberg and Ellinor Wargenbrant.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025